USA flag logo/image

An Official Website of the United States Government

System to analyze factors affecting human islet yield

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
80086
Program Year/Program:
2006 / SBIR
Agency Tracking Number:
DK070402
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
VITACYTE, LLC
1102 INDIANA AVE INDIANAPOLIS, IN 46202-5130
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2006
Title: System to analyze factors affecting human islet yield
Agency: HHS
Contract: 1R43DK070402-01A1
Award Amount: $195,331.00
 

Abstract:

DESCRIPTION (provided by applicant): The Edmonton Protocol is a breakthrough in the treatment of adult, type 1 diabetic patients and heralds a new era in transplantation medicine. Edmonton's success rate, as measured by insulin independence > 1 year post transplant, is comparable to whole organ pancreas transplantation. The major barrier for routine clinical adoption of the Protocol is the poor recovery of islets from human pancreata. Typically, 2 or more organs are usually required to recover a sufficient number of islets for successful transplantation. A combination of enzymatic & mechanical techniques are used to free islets from the pancreas. Improvements to the islet isolation procedure have been made incrementally since no laboratory has had the resources or expertise to critically evaluate the interaction of three factors that affect islet yield: histochemical composition of the organ, quality and composition of the tissue dissociation enzymes (TDEs), and the amount of endogenous pancreatic proteolytic enzymes generated during the tissue dissociation procedure. This grant focuses on evaluating the feasibility for developing a tissue test system (TTS) that will fill this gap. The TTS is similar to a biochemical enzyme assay: purified proteolytic enzymes are used to digest minced porcine pancreatic tissue (substrate) with free islet volume expressed as an islet equivalent number as the product of this interaction. We believe that the TTS will allow systematic evaluation of factors that affect islet yield and with this information we can rapidly assess modifications in the reagents and isolation process that can lead to improvements in the quality and yield of islets used in transplantation. The 3 goals of this grant will be to define the optimal experimental parameters for the TTS, compare the amount and quality of islets recovered from the TTS to those obtained from the established procedure, and develop a histochemical staining procedure to improve characterization of the tissue substrate. If successful, this project will be extended in a Phase II application to develop a human TTS. Development of a human TTS may be an innovative approach to improve knowledge of factors that affect islet yield. The ability to perform multiple analyses on tissue derived from an individual organ eliminates the problem of interpreting data between organs, enabling further research to develop improved TDE reagents and islet isolation procedures that will increase the recovery of islets from human pancreata.

Principal Investigator:

Robert C. Mccarthy
3179173457
vitacyte@indy.rr.com

Business Contact:


3179173457
VITACYTE@INDY.RR.COM
Small Business Information at Submission:

VITACYTE, LLC
1102 Stadium Drive INDIANAPOLIS, IN 46202

EIN/Tax ID: 470930763
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No